Conference Day Two

Thursday 30th March 2023

7:30 am
Morning Registration & Refreshments

8:20 am
Chairperson Opening Remarks

Exploring Human Breast Milk & Infant Formula

8:30 am Uncovering Opportunities for Precision Nutrition in the First 1000 Days of Life

  • Sharon Donovan Professor, University of Illinois at Urbana-Champaign


  • Reaffirming the importance of the first 1000 days in establishing health trajectories
  • Appreciating human milk as nature’s precision nutrition
  • STRONG kids 2 longitudinal birth cohort for precision nutrition

9:00 am Human Milk Oligosaccharides in Infant Formula Supplementation

  • Sophie Nutten Global Science & Allergy Lead, Nestle Health Science


  • Outlining how optimal infant nutrition is attributed to diverse bioactive components present in breast milk, such as human milk oligosaccharides (HMO), complex glycans that are abundant in human milk
  • Understanding the current availability of the complex glycans that are abundant in breast milk
  • Appreciating the importance of more prospective, randomized trials in infants comparing formulas with and without HMOs are still needed to evaluate the clinical effects of supplementation

9:30 am Examining Breast Milk Antibodies After COVID-19 Vaccination & Correlation with Maternal Immunization


  • Reviewing the physiology of breast milk antibody production
  • Discussing the role in passive protection to the infant
  • Outlining immunoglobulin transfer

10:00 am
Morning Break & Scientific Poster Session


Once the formal presentations are complete, let the learning and networking continue. The poster session allows you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships. During this session scientific posters will be presented on latest advancements in pre-clinical research

11:00 am Building Immunity Starting at Birth


  • Outlining the importance of numerous exposures leading to distinct immune
    responses largely driven by human glycoproteins and the cross-talk between
    the microbiome in the gut and the immune system
  • Discussing how Helaina are incorporating these glycoproteins in infant formula to enhance immunological properties
  • Understanding how Helaina’s product will bridge the gap between infant
    formula and the immunity properties breast milk provides

Assessing Microbiome-Directed Interventions to Optimize Product Development

11:30 am Tackling Complex Healthcare Challenges with Microbiome Based Products


  • Discussing the power in the science of EVC001, a strain used to tackle infant health issues
  • Delving into the imporance in driving industry forward to have a large scale impact
  • Exploring product efficacy and the ability to impact human health

12:00 pm Panel Discussion: Selecting the Optimal Bacterial Composition for Scientifically Backed Infant Microbiome Supplements


  • How should we select bacterial candidates and/or prebiotics to support microbiome development?
  • What functional tests should we conduct on bacterial strains to determine probiotic/LBP suitability?
  • The benefits and challenges of developing multi-strain versus single-strain supplements.

12:30 pm
Lunch Break & Networking

Streamlining Product Development to Advance Effective & Efficient Products to Market

1:30 pm Roundtables- Regulatory Differences: Food or Pharma?


Take the chance to dive into discussions exploring the differing regulatory landscapes across nutritional and therapeutic products

  • Approaching therapeutic applications
  • Exploring global differences

2:00 pm The Power of Microbiome Based Interventions: Product Development & Commercialization Across Maternal-Infant Products


  • Delving into case studies, practices and principles of what is required to influence a new standard of care
  • Discussing the importance of the rapidly commercializing products in this industry
  • Exploring the strong healthcare economic impact as a driving force

2:30 pm
Afternoon Comfort Break & Networking

2:45 pm Outlining Maternal Microbiome Directed Interventions to Improve Pregnancy & Infant Outcomes in LMIC Geographies


  • Rethinking why new tools are needed to achieve SDG mortality reduction targets and avert increasing morbidity due to maternal and neonatal conditions
  • Illuminating how the foundation plans to do this through their gut microbiome portfolio by shifting to underlying risk and moving earlier in the life course
  • Navigating plans to use an experimental medicine learning structure to accelerate and localize the approach to design and apply maternal microbiome directed interventions

3:15 pm Fireside Discussion: Geographical Considerations in Future Microbiome Therapeutic & Nutritional Interventions


  • Assessing whether geographical differences in maternal-infant microbiomes need to be considered more during product development
  • Discussing regional specific microbiome interventions that are in the market
  • Exploring future clinical considerations during product development

3:45 pm
Chairperson’s Closing Remarks

3:50 pm
End of Conference